The European Commission has granted conditional marketing authorization (Aic) for idecabtagene vicleucel (Ide-cel), the first T-cell based immunotherapy with chimeric antigen receptor (Car-T) directed against maturation antigen B cell (Bcma), for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and who have demonstrated disease progression to the last therapy. This was announced by Bristol Myers Squibb (Bms), noting that Ide-cel is the first and only approved Car-T therapy aimed at recognizing and binding to Bcma, a protein almost universally expressed on multiple myeloma cells, killing diseased cells.
Read Also
- Quirónsalud Marbella organizes a campaign to collect solidarity items in favor of the NGO DEBRA Piel de Mariposa May 28, 2021
- Third dose, Bassetti: “Decline in serious illness, confirmed by Israeli data” Sep 20, 2021
- Brentford achieves promotion to Premier League after 74 years May 30, 2021
- The HAS recommends generalizing screening for sickle cell disease to all newborns Nov 15, 2022
- Machine Tool Work Process Lancang Kuning Apr 14, 2021
- A doctor who was leaving surgery is the victim of a violent lock-in at the Vitacura service center Nov 24, 2022
- WHO identifies pathogens that may cause future pandemics Nov 21, 2022